Cognitive impairment in nondemented Parkinson's disease
Identifieur interne : 000301 ( Main/Corpus ); précédent : 000300; suivant : 000302Cognitive impairment in nondemented Parkinson's disease
Auteurs : Paolo Barone ; Dag Aarsland ; David Burn ; Murat Emre ; Jaime Kulisevsky ; Daniel WeintraubSource :
- Movement Disorders [ 0885-3185 ] ; 2011-12.
English descriptors
Abstract
A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23919
Links to Exploration step
ISTEX:9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognitive impairment in nondemented Parkinson's disease</title><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23919</idno><idno type="url">https://api.istex.fr/document/9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000301</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment in nondemented Parkinson's disease</title><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12">2011-12</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2483">2483</biblScope><biblScope unit="page" to="2495">2495</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E</idno><idno type="DOI">10.1002/mds.23919</idno><idno type="ArticleID">MDS23919</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CIND‐PD</term><term>Parkinson's disease</term><term>assessment</term><term>mild cognitive impairment</term><term>symptoms</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Paolo Barone MD, PhD</name><affiliations><json:string>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</json:string></affiliations></json:item><json:item><name>Dag Aarsland MD, PhD</name><affiliations><json:string>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</json:string></affiliations></json:item><json:item><name>David Burn MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University, United Kingdom</json:string></affiliations></json:item><json:item><name>Murat Emre MD, PhD</name><affiliations><json:string>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</json:string></affiliations></json:item><json:item><name>Jaime Kulisevsky MD, PhD</name><affiliations><json:string>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CIND‐PD</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mild cognitive impairment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>symptoms</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>assessment</value></json:item></subject><articleId><json:string>MDS23919</json:string></articleId><language><json:string>eng</json:string></language><abstract>A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.752</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>990</abstractCharCount><pdfWordCount>8268</pdfWordCount><pdfCharCount>56919</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>146</abstractWordCount></qualityIndicators><title>Cognitive impairment in nondemented Parkinson's disease</title><genre><json:string>review-article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>13</total><last>2495</last><first>2483</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23919</json:string></doi><id>9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cognitive impairment in nondemented Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Paolo Barone has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Dag Aarsland has received honoraria and research support from Merck Serono. David Burn has previously received honoraria from Merck Serono for acting in a medical advisory capacity. Murat Emre has previously received honoraria from Merck Serono for acting in a medical advisory capacity and for lectures. Jaime Kulisevsky has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Daniel Weintraub has previously received honoraria from Merck Serono for acting in a medical advisory capacity.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment in nondemented Parkinson's disease</title><author><persName><forename type="first">Paolo</forename><surname>Barone</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Università Federico II, Dipartimento di Scienze Neurologiche, Via Pansini 5, Naples, 80131, Italy</p></note><affiliation>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</affiliation></author><author><persName><forename type="first">Dag</forename><surname>Aarsland</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</affiliation></author><author><persName><forename type="first">David</forename><surname>Burn</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</affiliation></author><author><persName><forename type="first">Murat</forename><surname>Emre</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</affiliation></author><author><persName><forename type="first">Jaime</forename><surname>Kulisevsky</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2483">2483</biblScope><biblScope unit="page" to="2495">2495</biblScope></imprint></monogr><idno type="istex">9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E</idno><idno type="DOI">10.1002/mds.23919</idno><idno type="ArticleID">MDS23919</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>CIND‐PD</term></item><item><term>mild cognitive impairment</term></item><item><term>symptoms</term></item><item><term>assessment</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09-01">Received</change><change when="2011-07-21">Registration</change><change when="2011-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v26.14</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2011-12">December 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="140" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23919</doi><idGroup><id type="unit" value="MDS23919"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-09-01"></event><event type="manuscriptRevised" date="2011-07-06"></event><event type="manuscriptAccepted" date="2011-07-21"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-08-24"></event><event type="publishedOnlineFinalForm" date="2011-12-14"></event><event type="firstOnline" date="2011-08-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2483</numbering><numbering type="pageLast">2495</numbering></numberingGroup><correspondenceTo>Università Federico II, Dipartimento di Scienze Neurologiche, Via Pansini 5, Naples, 80131, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23919.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="129"></count><count type="wordTotal" number="11078"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cognitive impairment in nondemented Parkinson's disease<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Cognitive Impairment in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Paolo</givenNames><familyName>Barone</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>barone@unina.it</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Dag</givenNames><familyName>Aarsland</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>David</givenNames><familyName>Burn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Murat</givenNames><familyName>Emre</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Jaime</givenNames><familyName>Kulisevsky</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NO" type="organization"><unparsedAffiliation>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="TR" type="organization"><unparsedAffiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="ES" type="organization"><unparsedAffiliation>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">CIND‐PD</keyword><keyword xml:id="kwd3">mild cognitive impairment</keyword><keyword xml:id="kwd4">symptoms</keyword><keyword xml:id="kwd5">assessment</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Paolo Barone has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Dag Aarsland has received honoraria and research support from Merck Serono. David Burn has previously received honoraria from Merck Serono for acting in a medical advisory capacity. Murat Emre has previously received honoraria from Merck Serono for acting in a medical advisory capacity and for lectures. Jaime Kulisevsky has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Daniel Weintraub has previously received honoraria from Merck Serono for acting in a medical advisory capacity.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cognitive impairment in nondemented Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cognitive Impairment in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cognitive impairment in nondemented Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Barone</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurological Sciences, University Federico II‐ICD Hermitage, Capodimonte, Naples, Italy, and Schola Medica Salernitana, University of Salerno, Italy</affiliation><description>Correspondence: Università Federico II, Dipartimento di Scienze Neurologiche, Via Pansini 5, Naples, 80131, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dag</namePart><namePart type="family">Aarsland</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Psychiatric Division, Stavanger University Hospital and Akerhus University Hospital, University of Oslo, Stavanger, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Burn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murat</namePart><namePart type="family">Emre</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jaime</namePart><namePart type="family">Kulisevsky</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurology Department, Hospital de Sant Pau (IIB Sant Pau), CIBERNED and Autonomous University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-12</dateIssued><dateCaptured encoding="w3cdtf">2010-09-01</dateCaptured><dateValid encoding="w3cdtf">2011-07-21</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">129</extent><extent unit="words">11078</extent></physicalDescription><abstract lang="en">A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Paolo Barone has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Dag Aarsland has received honoraria and research support from Merck Serono. David Burn has previously received honoraria from Merck Serono for acting in a medical advisory capacity. Murat Emre has previously received honoraria from Merck Serono for acting in a medical advisory capacity and for lectures. Jaime Kulisevsky has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Daniel Weintraub has previously received honoraria from Merck Serono for acting in a medical advisory capacity.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>CIND‐PD</topic><topic>mild cognitive impairment</topic><topic>symptoms</topic><topic>assessment</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2483</start><end>2495</end><total>13</total></extent></part></relatedItem><identifier type="istex">9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E</identifier><identifier type="DOI">10.1002/mds.23919</identifier><identifier type="ArticleID">MDS23919</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000301 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000301 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:9A89F0CE3754B0A23F5E7DF5E4712ABC04D69B7E
|texte= Cognitive impairment in nondemented Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |